PROTACs (Proteolysis Targeting Chimeras) offer a revolutionary strategy to degrade proteins previously considered "undruggable." While the importance of the target protein ligand and linker is well-established, the strategic selection of an E3 ubiquitin ligase and its corresponding ligand is an equally critical but underexplored determinant of PROTAC efficacy and selectivity. This review systematically analyzes how E3 ligase-ligand pairing dictates degradation outcomes across diverse biological contexts. Our analysis, incorporating head-to-head comparisons, demonstrates that no single E3 ligand is universally superior. Instead, degradation efficiency is profoundly modulated by ternary complex cooperativity, cell-type specificity, and tissue distribution. CRBN-based degraders frequently excel in hematologic malignancies, while VHL-based PROTACs show advantages in certain solid tumors. We further highlight emerging E3 ligands (e.g., from IAP, DCAF families) as promising tools to overcome resistance and expand the degradable proteome. The review also explores innovative frontiers, including the potential for targeting non-protein substrates and the application of PROTACs as versatile chemical knockdown tools in research. Ultimately, this work underscores the central paradigm that "context dictates strategy" in E3 ligase selection, providing a critical framework for optimizing PROTAC design and broadening their therapeutic and research applications.
Brief description:
Toward optimizing PROTAC technology, this review systematizes the selection of E3 ligase ligands. Beginning with a comparative analysis of CRBN versus VHL, it expands the strategy to include emerging E3s for overcoming resistance, thereby establishing a refined and actionable framework for future degrader design.
DOI:10.1093/procel/pwaf107